Healthcare & Life Sciences

Latham offers life sciences and healthcare industry leaders deep sector knowledge, legal expertise, and commercial and government insight to meet client needs.

Why Latham

Melding Deep Industry Experience with Commercial Insight

Companies operating in the healthcare and life sciences sectors face an increasingly complex transactional, political, and competitive landscape. Latham’s superior grasp of the regulatory regimes and market issues means that clients can adroitly and expeditiously address litigation, mergers and acquisitions, capital raising, regulatory counseling, business restructuring and reorganization, contract negotiations, fraud and abuse compliance, white collar and government investigations, operational matters, and more.


For more information on Latham’s Healthcare experience and expertise visit the Healthcare Services & Providers Industry Group page

Life Sciences

For more information on Latham’s Life Sciences experience and expertise visit the Life Sciences Industry Group page

Awards & Rankings

  • Latham Again Named Technology Group of the Year - February 18, 2019
  • Latham Named Life Sciences Practice Group of the Year - January 27, 2019
  • Five Partners Receive 2018 MVP Recognition from Law360 - November 25, 2018
  • Firm and Judith Hasko Honored for Exceptional Life Sciences Work - September 16, 2018
  • Emerging Companies Partner Named Among San Diego's 50 Influential Leaders - September 06, 2018

Latham is known for offering "expert representation across the full scope of matters affecting life sciences and healthcare clients, including providers." They have a "strong bench of former government attorneys who field expertise across numerous US departments and offices" and a "dominant presence in qui tam suits and criminal proceedings, as well as frequent involvement in complex transactions, including high-value M&A.”

– Chambers USA 2018


Webcast: Recent Developments in Health Care Enforcement

Media Coverage

Technology Group of the Year: LathamPuma Beats Most of Stock Drop Suit Over Nerlynx Study StatementsLitigators of the Week: Latham’s Lethal IP Litigators Kill Patent Challenge to $2B-a-Year Drug


Latham Elects 22 New PartnersJury Reaches Verdict in Favor of Latham Client Puma Biotechnology Latham Named Life Sciences Practice Group of the Year

Thought Leadership

Drug Pricing and Payment Policy: HHS Rebate Reform ProposalDrug Pricing and Payment Policy: Key Developments and Potential Changes FDA Announces Planned Changes to the 510(k) Premarket Notification Program